Envoy Medical Inc. has announced the pricing of an upsized public offering, raising approximately $30 million upfront through the sale of 75 million shares of its Class A common stock (or pre-funded warrants in lieu thereof), accompanied by Series A-1 and Series A-2 common warrants. The Series A-1 warrants allow the purchase of up to 45 million shares, and the Series A-2 warrants allow the purchase of up to 75 million shares, both at a combined offering price of $0.40 per share. If fully exercised for cash, these milestone-linked warrants could generate up to an additional $48 million in gross proceeds for the company. Envoy Medical plans to use the funds for working capital, general corporate purposes, and to support its ongoing FDA pivotal clinical study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 283548) on February 11, 2026, and is solely responsible for the information contained therein.